JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tortella, F. C.
Right arrow Articles by Holaday, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tortella, F. C.
Right arrow Articles by Holaday, J. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PHENYTOIN SODIUM

U50,488, a highly selective kappa opioid: anticonvulsant profile in rats

FC Tortella, L Robles and JW Holaday

Subcutaneous or i.c.v. administration of U50,488, a highly selective kappa opioid agonist, resulted in a dose-and time-dependent anticonvulsant action in rats. The anticonvulsant effect was seizure- specific; thus, U50,488 protected against supramaximal electroshock seizures but failed to raise the threshold of flurothyl-induced convulsions. The ED50 for s.c. U50,488 was 8.6 mg/kg, with a duration of action longer than 8 hr. In contrast, the ED50 for i.c.v. U50,488 was 103.8 micrograms, lasting approximately 1 hr. The anticonvulsant effect of U50,488 was partially antagonized by high (10.0 mg/kg), but not low (1.0 mg/kg), doses of s.c. administered naloxone. Results indicate that U50,488 is an efficacious, long-acting anticonvulsant against supramaximal, but not chemical threshold, seizures in rats. Furthermore, the results with naloxone suggest that this effect of U50,488 is mediated by non-mu (probably kappa) binding sites. This structurally novel nonpeptide opioid may offer new insights into the development of therapeutically effective agents in the treatment of grand mal or partial epilepsies.

Volume 237, Issue 1, pp. 49-53, 04/01/1986
Copyright © 1986 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 BrainHome page
M. V. Solbrig, R. Adrian, J. Baratta, J. C. Lauterborn, and G. F. Koob
Kappa opioid control of seizures produced by a virus in an animal model
Brain, March 1, 2006; 129(3): 642 - 654.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
G. W. Terman, C. T. Drake, M. L. Simmons, T. A. Milner, and C. Chavkin
Opioid Modulation of Recurrent Excitation in the Hippocampal Dentate Gyrus
J. Neurosci., June 15, 2000; 20(12): 4379 - 4388.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
M. L. Simmons, G. W. Terman, and C. Chavkin
Spontaneous Excitatory Currents and kappa -Opioid Receptor Inhibition in Dentate Gyrus Are Increased in the Rat Pilocarpine Model of Temporal Lobe Epilepsy
J Neurophysiol, October 1, 1997; 78(4): 1860 - 1868.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1986 by the American Society for Pharmacology and Experimental Therapeutics.